TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug [Yahoo! Finance]
Royalty Pharma plc - Class A Ordinary Shares (RPRX)
US:NASDAQ Investor Relations:
ir.reprosrx.com/investor-relations
Company Research
Source: Yahoo! Finance
accelerate the development of Teva's anti-IL-15 antibody, TEV-'408. IL-15 plays a central role in driving multiple immune-mediated disease pathways. The candidate is currently in early-stage development for vitiligo and other autoimmune diseases. Royalty Pharma's $500 million commitment includes $75 million in R&D co-funding for a phase IIb vitiligo study expected to begin in 2026, with an option to invest a further $425 million to co-fund phase III development pending phase IIb results. If the drug is eventually approved and commercialized, Teva will pay Royalty Pharma a milestone payment and ongoing royalties on global net sales. Teva has strengthened its immunology pipeline through a strategic collaboration with Royalty Pharma, which significantly de-risks and accelerates the development of TEV-'408 for vitiligo. The partnership provides substantial non-dilutive funding to Teva, enabling faster clinical progression and positioning the company to move more efficiently through mi
Show less
Read more
Impact Snapshot
Event Time:
RPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RPRX alerts
High impacting Royalty Pharma plc - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
RPRX
News
- Teva Is No Longer A Turnaround Story, It's A Growth One [Seeking Alpha]Seeking Alpha
- Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Royalty Pharma promises $500M to Teva for advancing vitiligo treatment [Seeking Alpha]Seeking Alpha
- Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for VitiligoGlobeNewswire
- Royalty Pharma Announces Dividend IncreaseGlobeNewswire
RPRX
Sec Filings
- 1/13/26 - Form 4
- 1/7/26 - Form 144
- 1/6/26 - Form 3
- RPRX's page on the SEC website